Page last updated: 2024-12-06

6-thioxanthine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

6-thioxanthine: gpt/6-TXenzyme/prodrug pair is a promising alternative to the thymidine kinase gene and ganciclovir combination in the gene therapy of cancer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1268107
CHEMBL ID1426
SCHEMBL ID160703
SCHEMBL ID8485085
MeSH IDM0154307

Synonyms (53)

Synonym
nsc 12160
2h-purin-2-one, 1,3,6,7-tetrahydro-6-thioxo-
nsc12160
nsc-12160
2-hydroxy-6-mercaptopurine
6-thioxanthine
2002-59-7
6-thioxo-1,3,6,9-tetrahydro-purin-2-one
6-thioxo-3,9-dihydropurin-2-one
NCGC00161963-01
CHEMBL1426
AKOS005067757
6-sulfanylidene-3,7-dihydropurin-2-one
2hlr5dqg0j ,
ai3-52244
unii-2hlr5dqg0j
A814176
6-thioxo-3,7-dihydropurin-2-one;6-thioxo-6,9-dihydro-1h-purin-2(3h)-one
AKOS015955614
6-sulfanyl-9h-purin-2-ol
6-mercapto-9h-purin-2-ol
6-thioxo-6,9-dihydro-1h-purin-2(3h)-one
FT-0633971
6-sulfanyl-3,9-dihydro-2h-purin-2-one
STL372826
AKOS015854532
6-mercapto-3,9-dihydro-2h-purin-2-one
2-hydroxy-6-thiopurine
6-mercaptoxanthine
3,6-dihydro-6-thioxo-9h-purine-2(1h)-one
1,3,6,9-tetrahydro-6-thioxo-2h-purin-2-one
SCHEMBL160703
2-oxo-6-thioxo-1,2,3,6-tetrahydro-9h-purine
imidazolo[4, 5-d]pyrimidin-6(5h)-one, 4, 7-dihydro-4-thione-
6-thioxo-1,3,6,9-tetrahydro-2h-purin-2-one #
purin-2-ol, 6-mercapto (keto form)
6-thioxo-1,3,6,7-tetrahydro-purin-2-one
xanthine, 6-thio-
SCHEMBL8485085
DTXSID80173842
AKOS025395592
J-518826
mfcd01564486
GS-3736
2-hydroxy-6-mercapto-purin
STL558644
F12268
2h-purin-2-one, 1,3,6,9-tetrahydro-6-thioxo-
2h-purin-2-one, 1,3,6,7-tetrahydro-6-thioxo- xanthine, 6-thio-
6-thioxo-6,7-dihydro-1h-purin-2(3h)-one
6-thioxo-1,3,6,9-tetrahydro-2h-purin-2-one
CS-W019267
?6-thioxanthine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics2719

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ClpPBacillus subtilisPotency8.91251.995322.673039.8107AID651965
67.9K proteinVaccinia virusPotency22.38720.00018.4406100.0000AID720579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucose 6-dehydrogenaseRattus norvegicus (Norway rat)Ki54.00007.00007.00007.0000AID1520171
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID274556Antimalarial activity against Plasmodium falciparum 3D7 at 120 uM2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID1520171Inhibition of UDPGDH in rat hepatocytes after 20 to 120 secs by UV/Vis spectrophotometric analysis2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID96816In vitro inhibitory concentration required for 50% inhibition of L1210 cell growth1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID1520173Inhibition of UGT1A in rat hepatocytes preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1520172Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1767037Substrate activity at hexa-his tagged Helicobacter pylori XGHPRT assessed as apparent Km using purine base and PRib-PP as substrate measured for 60 sec by spectrophotometric method2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
AID1767036Substrate activity at Helicobacter pylori XGHPRT assessed as Kcat using purine base and PRib-PP as substrate measured for 60 sec by spectrophotometric method2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
AID274553Inhibition of [3H]hypoxanthine uptake into Plasmodium falciparum 3D7 at 120 uM2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID274549Inhibition of human HGPRT at pH 7.42006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID1767040Antibacterial activity against Helicobacter pylori assessed growth inhibition at 50 uM incubated for 3 days2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
AID274550Inhibition of Plasmodium falciparum HGXPRT at pH 7.42006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (22.58)18.7374
1990's7 (22.58)18.2507
2000's12 (38.71)29.6817
2010's4 (12.90)24.3611
2020's1 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]